Trevor enjoyed a long career with Fairfax Business Media writing on Australian equities for the AFR among other titles.
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.
The terms of the agreement are based on a minimum initial investment of $18 million for a 60% interest in Admedus Vaccines.
The company's Japanese subsidiary continues to be cash flow positive.
Revenue from the sale of Xprecia Stride™ Coagulation Analyser test strips was $500,000 in the March quarter of 2018.
The pilot project will assess the ResAppDx, ResApp’s smartphone application for diagnosing acute respiratory disease.
Ellex iTrack and Ellex tango™ offer surgeons restorative glaucoma therapy options.
Given recurring revenue streams provide earnings predictability, Volpara is a stock that could generate interest.